KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Receivables (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Change in Receivables for 6 consecutive years, with $39.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 90.14% year-over-year to $39.7 million, compared with a TTM value of $55.6 million through Dec 2025, down 25.95%, and an annual FY2025 reading of $55.6 million, down 25.95% over the prior year.
  • Change in Receivables was $39.7 million for Q4 2025 at AbCellera Biologics, up from $3.4 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $39.7 million in Q4 2025 and bottomed at -$7.9 million in Q1 2023.
  • Average Change in Receivables over 5 years is $11.8 million, with a median of $10.8 million recorded in 2023.
  • Peak annual rise in Change in Receivables hit 1900.0% in 2023, while the deepest fall reached 190.45% in 2023.
  • Year by year, Change in Receivables stood at $3.1 million in 2021, then soared by 522.83% to $19.0 million in 2022, then crashed by 45.18% to $10.4 million in 2023, then skyrocketed by 99.86% to $20.9 million in 2024, then surged by 90.14% to $39.7 million in 2025.
  • Business Quant data shows Change in Receivables for ABCL at $39.7 million in Q4 2025, $3.4 million in Q3 2025, and $11.4 million in Q2 2025.